Skip to Main Content
Table II.

Development of EAE by Adoptive Transfer with Tg Th1 Cell Lines



Ascending paralysis a

Dysphagia b

Abnormal gait c
Tg T cells
 
Incidence
 
Severity
 
Onset
 
Incidence
 
Weight loss (%)
 
Onset
 
Incidence
 
Onset
 
MS2-3C8 (B6) 11/19 1.8 ± 0.8 16 ± 4 10/19 23 ± 6 19 ± 3 10/19 18 ± 3 
MS2-3C8 (B6)–Rag-1−/− 13/13 2.0 ± 0.8 8 ± 2 8/13 27 ± 4 11 ± 1 0/13 – 
MS2-3C8 (G2) 7/9 2.1 ± 0.4 14 ± 6 5/9 21 ± 5 20 ± 5 1/9 25 
HD4-1C2
 
0/9
 

 

 
0/9
 

 

 
0/9
 

 


Ascending paralysis a

Dysphagia b

Abnormal gait c
Tg T cells
 
Incidence
 
Severity
 
Onset
 
Incidence
 
Weight loss (%)
 
Onset
 
Incidence
 
Onset
 
MS2-3C8 (B6) 11/19 1.8 ± 0.8 16 ± 4 10/19 23 ± 6 19 ± 3 10/19 18 ± 3 
MS2-3C8 (B6)–Rag-1−/− 13/13 2.0 ± 0.8 8 ± 2 8/13 27 ± 4 11 ± 1 0/13 – 
MS2-3C8 (G2) 7/9 2.1 ± 0.4 14 ± 6 5/9 21 ± 5 20 ± 5 1/9 25 
HD4-1C2
 
0/9
 

 

 
0/9
 

 

 
0/9
 

 

The source of the Th1 cell line and the number of mice out of each experiment showing any sign of disease are indicated as well as the mean day of onset ± SD. 10–20 million cells were transferred i.v. after 4 d of in vitro stimulation with human MBP 111–129. Pertussis toxin was administered i.v. on days 0 and 2. Clinical symptoms were divided into three groups to distinguish aascending paralysis from the atypical symptoms of bdysphagia with accompanying weight loss (>20% body weight) and difficulties swallowing or cabnormal gait including spinning, head-tilt and loss of coordinated movement. Ascending paralysis on a scale of 0–4: 0, no symptoms; 1, limp tail; 2, hindlimb weakness; 3, hindlimb paralysis; 4, hindlimb and forelimb paralysis. Dysphagia described as the percentage of weight loss compared with peak body weight over course ± SD. Results were pooled from two to five independent experiments.

Close Modal

or Create an Account

Close Modal
Close Modal